Seattle Genetics Profile |
62.37 |
|
| 57.51 | Last Month High 64.08 |
| 62.27 | Trading Day High 64.08 |
Advice Valuation Profit Patterns
October 24, 2017 updated 1 hour ago
Exercise or conversion by Clay Siegall of 1797 shares of Seattle Genetics subject to Rule 16b-3
| Seattle Genetics Inc insider trading alert for exercise of non-qualified stock option (right to buy) by Clay Siegall, President and CEO, on October 13, 2017. This event was filed by Seattle Genetics Inc with SEC on 2017-10-13. Statement of changes in beneficial ownership - SEC Form 4. Clay Siegall is currently serves as co-founder, chairman, ceo and pres of Seattle Genetics Inc [view details] |
Seattle Genetics Summary
Seattle Genetics Inc (SGEN) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 759 people. Seattle Genetics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 9.13 B. Seattle Genetics Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 143.03 M outstanding shares of which 10.98 M shares are at this time shorted by private and institutional investors with about 9.81 trading days to cover.
SEATTLE GENETICS currently holds about 452.41 M in cash with (154.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.16.
Check Seattle Genetics Probability Of Bankruptcy
Ownership Allocation (%)
Top Holders
| Category | |||
 | Stlmt ID NASDAQ Biotechnology | US Index | |
 | NQ US Biotech Large Mid Cap GB | US Index | |
 | NASDAQ Biotechnology Total Retu | US Index | |
 | NASDAQ Composite Total Return I | US Index |
Key Fundamentals
| Return On Asset | (15.95) % | ||
| Profit Margin | (47.38) % | ||
| Operating Margin | (48.22) % |
Seattle Genetics Against Markets
Risk Adjusted Performance Score (0 to 100) | 21 |
Chance of | < 28% |
Seattle Genetics Inc
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. more
 |
| ||
| Name | Seattle Genetics Inc | ||
| Analyst Consensus | |||
| Piotroski F Score | |||
| Macroaxis Advice | |||
Specialization | Healthcare, Pharmaceuticals And Biosciences | ||
| Instrument | USA Stock Stocks Directory | ||
| Region | North America | ||
| Location | WASHINGTON, U.S.A | ||
| Business Address | 21823 30th Drive S.E., Bothell, WA 98021, United States | ||
| Exchange | NASDAQ | ||
| CIK Number | 01060736.0 | ||
| ISIN | US8125781026 | ||
| CUSIP | 812578102 | ||
| Sector | Healthcare | ||
| Industry | Biotechnology | ||
| Benchmark | DOW | ||
| Website | www.seattlegenetics.com | ||
| Contact Number | 425 527 4000 | ||
| Currency | USD - US Dollar |
Recommendations
Seattle Genetics Analyst Recommendations
| Target Price | Advice | # of Analysts | |
| 57.73 | Hold | 11 | Odds |
| Seattle Genetics Analyst Advice |
Opportunities
Explore Investment Opportunities
Earnings
Seattle Genetics Earnings Estimates
| EPS | Estimate Date | ||
|---|---|---|---|
| Quarterly Estimate | -0.42 | April 27, 2017 |
| Earnings Estimate |